A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia.

Trial Profile

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Niacin
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type V
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 05 May 2009 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
    • 01 Dec 2008 Results published in the International Journal of Clinical Practice.
    • 01 Dec 2008 Primary endpoint 'Low density lipoprotein cholesterol level' has been met according to results published in the International Journal of Clinical Practice.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top